The role of type I interferons (IFNs) in mediation of acute viral symptoms (fever, somnolence, anorexia, etc.) is unknown. To determine the role of type I IFN in selected symptom development, body temperature and sleep responses to a marginally lethal dose of X-31 inXuenza virus were examined in mice with a targeted mutation of the IFN receptor type I (IFN-RI knockouts) and compared to wildtype 129 SvEv control mice. Mice were monitored for 48 h to determine baseline temperature and sleep proWles prior to infection, and then for 9 days following infection. Hypothermic responses to virus were perceptible beginning at 64 h post-infection (PI) and were more marked in KO mice until 108 h, when hypothermia became more exaggerated in wild-type controls. Temperatures of wild-type mice continued to decline through day 9 while temperatures in IFN-RI KO mice stabilized. Time spent in non-rapid eye movement sleep (NREMS) increased in KO mice when hypothermia was marked and then returned to baseline levels, while NREMS continued to increase in wild-type mice through day 9. Other sleep parameters [time spent in rapid eye movement sleep (REMS), relative NREMS EEG slow wave activity, NREMS EEG power density] were all reduced in wild-type mice compared to KOs from days 3 to 8 while REMS low frequency EEG power density increased in wild-type relative to KOs. In conclusion, our results indicate that the presence of functional type I IFN slightly ameliorates disease symptoms early in the X-31 infection while exacerbating disease symptoms later in the infection.
Introduction
In recent years it has been recognized that the collective symptoms of an acute infection [variously termed the 'Xu' syndrome, sickness behavior, or the acute phase response (APR)] reXect adaptive physiological responses that promote recovery from infection (Dantzer, 2004) . Therefore, the APR can be considered a form of innate immunity to infection that is regulated predominantly by proinXammatory cytokines (Dantzer, 2004) . While the viral APR cannot be distinguished from the bacterial APR on symptomatic grounds, viral illness is frequently accompanied by circulating type I interferons (IFNs) (Gendrel et al., 1999) that are rarely detectable in bacterial infections. Type I IFNs are considered protective in viral infections and are deWned currently as those antiviral cytokines that bind to the type I IFN receptor. Type I IFNs consist of IFN (several subtypes), IFN , IFN , IFN , IFN , IFN and IFN at present (Chen et al., 2004a) ; IFN and IFN are the best characterized type I IFNs. Highly puriWed or cloned type I IFNs induce a Xu-like syndrome when given in pharmacological doses (Quesada et al., 1986; Goebel et al., 2002) . Therefore, it is generally assumed that type I IFNs potentiate the viral APR, though many other cytokines known to be APR mediators are also induced by viruses (Majde, 2000) . The exact role of type I IFNs as mediators of viral disease symptoms is unknown.
